We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · July 20, 2021

Emtricitabine and Tenofovir Alafenamide for HIV Prophylaxis

The Lancet HIV


Additional Info

The Lancet HIV
Long-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide vs Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results From a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet HIV 2021 Jul 01;8(7)e397-e407, O Ogbuagu, PJ Ruane, D Podzamczer, LC Salazar, K Henry, DM Asmuth, D Wohl, R Gilson, Y Shao, R Ebrahimi, S Cox, A Kintu, C Carter, M Das, JM Baeten, DM Brainard, G Whitlock, JM Brunetta, G Kronborg, CD Spinner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading